Relax, Teva and Allergan investors. The companies are on track to close their whopper knockoffs deal in the first half of June or so, one analyst says.
According to Bernstein’s Ronny Gal, Teva has now sold off all the already-marketed products it needed to jettison in order to close its $40.5 billion buy of Allergan’s generics unit. It’s started casting off pipeline assets, too, and once it’s officially selected buyers for all of its candidates, it’ll submit a data package to the FTC and the body will vote on approving the transaction. Timeline: three to four weeks, Gal figures.
Shareholders have been antsy since the pair announced the acquisition last summer. Teva, for one, needs the extra revenue to boost its sagging generics unit, especially now that generic Copaxone is taking its toll on branded sales, too. And Allergan, who recently saw its Pfizer buyout scuttled by the U.S. Treasury, is eager to get the cash in its hands and start bulking up again through its own buys.
And news of a delay on the closing–initially scheduled for Q1 of this year–has only stoked their fears. “We continue to be surprised by how much play the conspiracy theories around the deal have gotten,” Gal wrote.
As he’s reassured investors, though, the holdup is just the FTC. The agency still has 5 or 6 pipeline products it needs to make decisions on, Gal noted, meaning one more wave of sales could follow.
Meanwhile, across the pond, the companies are good to go. Last month, Teva nabbed an expedited antitrust approval after agreeing to sell off the bulk of Allergan’s current generics business in the U.K. and Ireland; discard its own business in Iceland; and part ways with molecules in 24 other countries in Europe.
By Carly Helfand
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”